This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: VE-2851

February 2019 Br J Cardiol 2019;26:10

New anticoagulant drug class in development

BJC Staff

Abstract

It is hoped that PROACs might become the first anticoagulants suitable for long-term co-administration with antiplatelet drugs for patients with coronary artery disease due to their novel combination of efficacy, low bleeding, and sparing of platelet function that was observed in preclinical testing. Many patients worldwide could potentially benefit from safe, long-term therapy combining an oral anticoagulant with one or more antiplatelet drugs (e.g. aspirin, clopidogrel) to prevent stroke or heart attack. Current combination treatments with direct oral anticoagulants (DOACs) are generally limited to 12 months because of the increased risk of

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now